Challenges in developing drugs for pediatric CNS disorders: A focus on psychopharmacology

Area of Science:

• Neuroscience
• Pediatric Psychiatry
• Clinical Pharmacology

Background:

• Childhood psychiatric disorders require early intervention to prevent long-term disability.
• Pediatric drug development for central nervous system (CNS) indications is limited, with testing often an afterthought.
• Decreasing pharmaceutical funding for neuroscience research exacerbates challenges in pediatric drug development.

Purpose of the Study:

• To highlight challenges in pediatric drug development for psychiatric disorders.
• To present opportunities and new strategies for de-risking investigational drugs in pediatric CNS indications.
• To review current trends, regulatory landscapes, and funding opportunities for pediatric psychiatric drug development.

Main Methods:

• Review of current trends in pediatric drug efficacy testing in academic and industry trials.
• Discussion of the regulatory landscape for pediatric drug testing.
• Identification of obstacles and presentation of new clinical trial designs and funding models.

Main Results:

• Pediatric testing for CNS psychiatric indications is often delayed until after adult efficacy is established.
• Limited funding and a lack of early pediatric focus hinder the development of new treatments.
• Existing policies aim to encourage pediatric testing, but significant obstacles remain.

Conclusions:

• Addressing challenges in pediatric drug development is crucial for early intervention in psychiatric disorders.
• Innovative clinical trial designs and funding strategies are necessary to de-risk investigational drugs for pediatric CNS indications.
• A proactive approach to pediatric drug development is essential to improve long-term outcomes for children with psychiatric conditions.